L Ingle1, J G Cleland2, A L Clark3. 1. Department of sport, health & exercise science, university of Hull, 003 Don building, Cottingham road, Kingston-upon-Hull, HU7 6RX, United Kingdom. Electronic address: L.Ingle@hull.ac.uk. 2. National heart & lung institute, Royal Brompton & Harefield hospitals, Imperial college, London, United Kingdom. 3. Department of academic cardiology, Hull York medical school, Castle Hill hospital, Kingston-upon-Hull, HU16 5JQ, United Kingdom.
Abstract
OBJECTIVE: To assess the prognostic implications of the 6-minute walk test (6-MWT) distance measured twice, one year apart, in a large sample of patients with chronic heart failure (CHF) followed for an extended period (>8 years from baseline). MATERIAL AND METHODS: Patients undertook a 6-MWT at baseline and at one year, and were followed up for 8 years from baseline. RESULTS: Six hundred patients (median [inter-quartile range, IQR]) (age 78 [72-84] years; 75% males; body mass index 27 [25-31] kg·m(-2); left ventricular ejection fraction 34 [26-38] %) were included. At baseline, median 6-MWT distance was 232 (60-386) m. There was no significant change in 6-MWT distance at one year (change -12m; P=0.533). During a median follow-up of 8.0 years in survivors, 396 patients had died (66%). Four variables were independent predictors of all-cause mortality in a multivariable Cox model (adjusted for body mass index, age, QRS duration, left ventricular ejection fraction); increasing NT pro-BNP, decreasing 6-MWT distance at 1 year, decreasing haemoglobin, and increasing urea. CONCLUSIONS: Distance walked during the 6-MWT is an independent predictor of all-cause mortality in patients with CHF. In survivors, the 6-MWT distance is stable at 1 year. The 6-MWT distance at 1 year carries similar prognostic information.
OBJECTIVE: To assess the prognostic implications of the 6-minute walk test (6-MWT) distance measured twice, one year apart, in a large sample of patients with chronic heart failure (CHF) followed for an extended period (>8 years from baseline). MATERIAL AND METHODS:Patients undertook a 6-MWT at baseline and at one year, and were followed up for 8 years from baseline. RESULTS: Six hundred patients (median [inter-quartile range, IQR]) (age 78 [72-84] years; 75% males; body mass index 27 [25-31] kg·m(-2); left ventricular ejection fraction 34 [26-38] %) were included. At baseline, median 6-MWT distance was 232 (60-386) m. There was no significant change in 6-MWT distance at one year (change -12m; P=0.533). During a median follow-up of 8.0 years in survivors, 396 patients had died (66%). Four variables were independent predictors of all-cause mortality in a multivariable Cox model (adjusted for body mass index, age, QRS duration, left ventricular ejection fraction); increasing NT pro-BNP, decreasing 6-MWT distance at 1 year, decreasing haemoglobin, and increasing urea. CONCLUSIONS: Distance walked during the 6-MWT is an independent predictor of all-cause mortality in patients with CHF. In survivors, the 6-MWT distance is stable at 1 year. The 6-MWT distance at 1 year carries similar prognostic information.
Authors: Iván José Fuentes-Abolafio; Brendon Stubbs; Luis Miguel Pérez-Belmonte; María Rosa Bernal-López; Ricardo Gómez-Huelgas; Antonio Ignacio Cuesta-Vargas Journal: BMC Cardiovasc Disord Date: 2020-12-09 Impact factor: 2.298